Aptevo Therapeutics(APVO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 3Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress Additional Favorable Data to be Presented at the Society for Immunotherapy of Ca ...